# Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

> **NCT00718965** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 826 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** AVE5530
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00718965
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2008-11
- **Final completion:** 2009-06
- **Target enrollment:** 826 (ACTUAL)
- **Why stopped:** AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy
- **Last updated:** 2016-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718965, "Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00718965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*